Anti-Cancer Drug Discovery and Development
The development of drugs designed to selectively inhibit and slow tumour growth has entered a dynamic and promising phase, driven by a targeted approach. Over the past decade, researchers have identified specific proteins involved in cancer cell proliferation, enabling the creation of therapies that directly act on these molecular targets. While drug discovery still relies on a combination of high-throughput screening and rational design, the landscape is evolving. The collaboration between academic institutions and the pharmaceutical industry continues to adapt, shaped by both technical innovations and financial pressures. At the core of these efforts lies a shared commitment to translating cutting-edge scientific discoveries into tangible clinical treatments.